Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-14 08:50 am Sale | 13G | JOUNCE THERAPEUTICS INC. JNCE | Deep Track Capital LP | 0 0% | -4,259,653 (Position Closed) | View |
| 2024-02-09 4:05 pm Sale | 13G | JOUNCE THERAPEUTICS INC. JNCE | Opaleye Management Inc. | 0 0% | -2,810,000 (Position Closed) | View |
| 2024-02-02 12:28 pm Sale | 13G | JOUNCE THERAPEUTICS INC. JNCE | Cowen Financial Products LLC | 0 0% | -3,647,430 (Position Closed) | View |
| 2023-05-05 4:34 pm Sale | 13D | JOUNCE THERAPEUTICS INC. JNCE | TANG CAPITAL PARTNERS LP | 10,000 100% | -5,290,087 (-99.81%) | View |
| 2023-04-12 4:15 pm Purchase | 13G | JOUNCE THERAPEUTICS INC. JNCE | Opaleye Management Inc. | 2,810,000 5.39% | 2,810,000 (New Position) | View |
| 2023-04-07 4:00 pm Unchanged | 13D | JOUNCE THERAPEUTICS INC. JNCE | TANG CAPITAL PARTNERS LP | 5,300,087 10.2% | 0 (Unchanged) | View |
| 2023-03-28 4:00 pm Unchanged | 13D | JOUNCE THERAPEUTICS INC. JNCE | TANG CAPITAL PARTNERS LP | 5,300,087 10.2% | 0 (Unchanged) | View |
| 2023-03-17 4:00 pm Unchanged | 13D | JOUNCE THERAPEUTICS INC. JNCE | TANG CAPITAL PARTNERS LP | 5,300,087 10.2% | 0 (Unchanged) | View |
| 2023-03-14 5:00 pm Purchase | 13D | JOUNCE THERAPEUTICS INC. JNCE | TANG CAPITAL PARTNERS LP | 5,300,087 10.2% | 300,087 (+6.00%) | View |
| 2023-03-06 4:00 pm Purchase | 13G | JOUNCE THERAPEUTICS INC. JNCE | TANG CAPITAL PARTNERS LP | 5,000,000 9.7% | 5,000,000 (New Position) | View |
| 2023-02-14 4:30 pm Sale | 13G | JOUNCE THERAPEUTICS INC. JNCE | ORBIMED ADVISORS LLC | 0 0% | -2,200,200 (Position Closed) | View |
| 2023-02-14 4:06 pm Sale | 13G | JOUNCE THERAPEUTICS INC. JNCE | PFM Health Sciences LP | 345,926 0.7% | -3,626,942 (-91.29%) | View |
| 2023-02-14 4:06 pm Sale | 13G | JOUNCE THERAPEUTICS INC. JNCE | Third Rock Ventures II L.P. | 335,533 0.6% | -3,794,934 (-91.88%) | View |
| 2023-02-14 10:07 am Purchase | 13G | JOUNCE THERAPEUTICS INC. JNCE | RTW INVESTMENTS LP | 5,106,341 9.9% | 2,243,143 (+78.34%) | View |
| 2023-02-14 08:40 am Purchase | 13G | JOUNCE THERAPEUTICS INC. JNCE | Deep Track Capital LP | 4,259,653 8.24% | 259,653 (+6.49%) | View |
| 2023-02-14 08:23 am Purchase | 13G | JOUNCE THERAPEUTICS INC. JNCE | BANK OF AMERICA CORP BAC | 3,276,699 6.3% | 3,276,699 (New Position) | View |
| 2023-01-23 3:48 pm Purchase | 13G | JOUNCE THERAPEUTICS INC. JNCE | Cowen Financial Products LLC | 3,647,430 7.05% | 567,078 (+18.41%) | View |
| 2022-04-22 10:54 am Purchase | 13G | JOUNCE THERAPEUTICS INC. JNCE | Cowen Financial Products LLC | 3,080,352 5.96% | 3,080,352 (New Position) | View |
| 2022-02-14 4:52 pm Sale | 13G | JOUNCE THERAPEUTICS INC. JNCE | Third Rock Ventures II L.P. | 4,130,467 8.1% | -8,209,361 (-66.53%) | View |
| 2022-02-14 12:37 pm Purchase | 13G | JOUNCE THERAPEUTICS INC. JNCE | PFM Health Sciences LP | 3,972,868 7.8% | 1,584,801 (+66.36%) | View |